COSIMO – patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study
Sign Up to like & getrecommendations! Published in 2018 at "Thrombosis Journal"
DOI: 10.1186/s12959-018-0176-2
Abstract: BackgroundAround 20% of venous thromboembolism (VTE) cases occur in patients with cancer. Current guidelines recommend low molecular weight heparin (LMWH) as the preferred anticoagulant for VTE treatment. However, some guidelines state that vitamin K antagonists… read more here.
Keywords: vte; treatment; rivaroxaban treatment; cosimo ... See more keywords